Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geographic Atrophy (GA) Clear all
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525600
View directory record Official record
Conditions
Geographic Atrophy
Interventions
APL-2, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
73
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

NCT01802866
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ACU-4429, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 13, 2026, 11:22 AM EDT
Recruiting No phase listed Observational

Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

NCT07556406
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Optical coherence tomography, Microperimetry
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2 Interventional

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

NCT04656561
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ANX007, Sham comparator
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 13, 2026, 11:22 AM EDT
Recruiting No phase listed Observational

Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).

NCT07582042
View directory record Official record
Conditions
Geographic Atrophy From Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
65 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Not listed Phase 2 Interventional

The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)

NCT00485394
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
OT-551, vehicle placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated No phase listed Observational

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

NCT03894020
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
Interventions
Not listed
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

NCT02686658
View directory record Official record
Conditions
Geographic Atrophy, Dry Age-Related Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug · Other
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

NCT00695318
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
55 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 13, 2026, 11:22 AM EDT
Not listed No phase listed Observational

Non Exudative AMD Imaged With SS-OCT- Extension

NCT04469140
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 13, 2026, 11:22 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445
View directory record Official record
Conditions
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
Drug · Other
Lead sponsor
ONL Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Not listed No phase listed Observational

Non Exudative AMD Imaged With SS-OCT

NCT03688243
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting No phase listed Observational

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

NCT05797896
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
250 participants
Timeline
2023 – 2027
U.S. locations
10
States / cities
Glendale, California • Mountain View, California • Carmel, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

NCT01632527
View directory record Official record
Conditions
Age Related Macular Degeneration, Macular Degeneration, AMD
Interventions
HuCNS-SC cells
Drug
Lead sponsor
StemCells, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2015 · Synced Sep 13, 2026, 11:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

NCT07392255
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
CTx001
Genetic
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

NCT03777332
View directory record Official record
Conditions
Geographic Atrophy
Interventions
PEGCETACOPLAN (APL-2)
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Bakersfield, California • Beverly Hills, California • Encino, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting Phase 3 Interventional

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731
View directory record Official record
Conditions
Age Related Macular Degeneration (ARMD)
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
55 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT03295877
View directory record Official record
Conditions
Geographic Atrophy
Interventions
RO7171009
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Bakersfield, California • Mountain View, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT01342926
View directory record Official record
Conditions
Atrophy, Geographic
Interventions
GSK933776, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
55 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT05839041
View directory record Official record
Conditions
Geographic Atrophy of the Macula, Macular Degeneration
Interventions
AVD-104, Avacincaptad
Drug
Lead sponsor
Aviceda Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

NCT02503332
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06961370
View directory record Official record
Conditions
Geographic Atrophy, Age-related Macular Degeneration
Interventions
RO7669330, Syfovre™, Izervay™
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Vonaprument, Sham Administration
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525613
View directory record Official record
Conditions
Geographic Atrophy
Interventions
APL-2, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
67
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 13, 2026, 11:22 AM EDT